PARP1 and APE1 mRNA expression might correlate with the cytotoxic efficacy of talazoparib and APE1 inhibitor III in MDS/CMML and AML cells and explain why some of the patients did not respond to the drugs. Here, PARP1 is linked to myelodysplastic syndrome.